A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Launched by ASTRAZENECA · Nov 14, 2018

Keywords

ClinConnect Summary

This clinical trial is testing new cancer treatments for women with metastatic triple-negative breast cancer (TNBC), a type of breast cancer that is more challenging to treat. The study is exploring the safety and effectiveness of a medication called durvalumab, either on its own or combined with other new therapies, including a drug called paclitaxel. The goal is to find out if these treatments can help patients who have not received any prior treatment for their advanced cancer.

To join the trial, participants must be women aged 18 or older, have confirmed advanced or metastatic TNBC, and have at least one measurable tumor that hasn't been treated with radiation. Importantly, candidates should not have had any previous treatments for their metastatic cancer. During the trial, participants will receive the study medications and will be closely monitored for the effects and any potential side effects. This research is crucial as it may lead to better treatment options for women facing this difficult diagnosis.

Gender

FEMALE

Eligibility criteria

• • Inclusion criteria
• • 1. Female
• • 2. At least 18 years of age at the time of screening
• • 3. Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
• • 4. No prior treatment for metastatic (Stage IV) TNBC
• • 5. Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
• • 6. WHO/ECOG status at 0 or 1 at enrollment
• • Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)
• • Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay
• • Exclusion criteria
• • 1. History of allogeneic organ transplantation
• • 2. Active or prior documented autoimmune or inflammatory disorders
• • 3. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen \[HBsAg\] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
• • 4. Untreated CNS metastases
• • 5. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
• • 6. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
• • 7. Female patients who are pregnant, breastfeeding
• • 8. Cardiac Ejection Fraction less than 50%
• Patients enrolled in Arm 2 only:
• • 1. Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
• • 2. Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
• • 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
• • 4. Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
• • Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months
• • Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.
• Patients enrolled in Arm 6, 7 and 8 only:
• • 1. History of or active interstitial lung disease/pneumonitis
• • 2. Use of chloroquine or hydroxychloroquine in \<14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
• • 3. Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.